After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. The stock was recently discussed on Yahoo Finance as it revealed that Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2023 Revenue.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
Standard BioTools Inc is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Diagnostics & Research industry. At the end of the last regular session, the stock closed at $2.43 and fluctuated between $2.4600 as its day high and $2.2300 as its day low. The current market capitalization of Standard BioTools Inc is $703.39M. A total of 2.5 million shares were traded on the day, compared to an average of 1.15M shares.
Insider Activity
Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, LAB has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 23 BUYs and 3 SELLs from insiders. Insiders purchased 2,283,143 shares during that period but sold 143,762.
In the most recent transaction, Casdin Eli bought 800,000 shares of LAB for 2.29 per share on May 19. After the transaction, the Director now owns 1,200,000 company shares. In a previous transaction on May 19, Casdin Partners Master Fund, L bought 800,000 shares at 2.29 per share. LAB shares that Director owns now total 1,200,000.
Among the insiders who bought shares, Black Jeffrey G. acquired of 42,492 shares on May 19 at a per-share price of $2.29. This resulted in the SVP & Chief Financial Officer holding 85,984 shares of LAB after the transaction. In another insider transaction, Casdin Partners Master Fund, L bought 150,000 shares at $2.16 per share on May 18. Company shares held by the Director now total 400,000.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for LAB in the last 3 months, the mean price target is $4.00 with high estimates of $4.00 and low estimates of $4.00. In terms of 52-week highs and lows, LAB has a high of $3.16 and a low of $1.46.
As of this writing, LAB has an earnings estimate of $0 per share for the current quarter. EPS was calculated based on a consensus of 0 estimates, with a high estimate of $0 per share and a lower estimate of $0.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. LAB’s latest balance sheet shows that the firm has $28.45M in Cash & Short Term Investments as of fiscal 2021. There were $111.65M in debt and $49.57M in liabilities at the time. Its Book Value Per Share was -$1.66, while its Total Shareholder’s Equity was $94.60M.
Analysts Opinion
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for LAB is Buy with a score of 5.00.
